Halozyme Therapeutics' GAAP net income for 3 months of 2022 was $60.108 million, up 2.2 times from $27.895 million in the previous year. Revenue increased 31.7% to $117.279 million compared to $89.022 million a year earlier.
Halozyme Therapeutics' GAAP net income for 3 months of 2022 was $60.108 million, up 2.2 times from $27.895 million in the previous year. Revenue increased 31.7% to $117.279 million compared to $89.022 million a year earlier. 
ir.halozyme.com
English (US) 